ZipPrime

Executive Summary

ZipPrime is pioneering a transformative approach to liquid biopsy by addressing the critical challenge of capturing and preserving rare circulating free DNA (cfDNA) at the single-molecule level. Traditional cfDNA analysis suffers from low sensitivity and reproducibility due to the fragility and scarcity of these molecules. ZipPrime's all-in-one solution uses advanced molecular tagging and detection technology to capture even a single copy of cfDNA, significantly improving the accuracy and consistency of downstream assays. This capability is essential for early cancer detection, monitoring minimal residual disease, and non-invasive prenatal testing, where precision is paramount. The company's platform integrates AI-driven analytics to enhance signal-to-noise ratio, enabling robust quantification and mutation detection from minute sample volumes. By preserving the integrity of cfDNA from collection to analysis, ZipPrime eliminates a major bottleneck in liquid biopsy workflows, potentially unlocking broader clinical adoption and improving patient outcomes. Founded in 2021 and based in London, ZipPrime operates at the intersection of AI and drug discovery, serving the rapidly growing liquid biopsy market. The company has developed proprietary chemistry and microfluidics that stabilize cfDNA before it degrades, a significant advantage over existing methods. While still in early stages (no disclosed funding or partnerships), the technology has strong potential to become a standard for cfDNA processing in research and clinical settings. Key upcoming milestones include validation studies with academic collaborators and initial commercial pilots with diagnostics partners. ZipPrime's differentiated single-molecule approach positions it well to capture value in a market projected to exceed $10 billion by 2030, provided it executes on its development roadmap and secures strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Publication of peer-reviewed validation study demonstrating single-molecule cfDNA capture accuracy70% success
• Q2 2027Strategic partnership with a major diagnostics company for cfDNA assay development50% success
• Q1 2027Completion of Series A funding round to scale commercial operations60% success